- Appointed Head of Development and Medical Affairs.
- In charge of the acceleration of the international clinical
development of VALEDIA®, its industrial production with
Pierre Fabre, the integration of the product into public prevention
plans and the obtention of the reimbursement.
LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News:
VALBIOTIS (FR0013254851 – ALVAL/PEA/SME eligible) (Paris:ALVAL),
a French Research & Development company committed to scientific
innovation for preventing and combating metabolic diseases, confirms
its international expansion with the appointment of Murielle CAZAUBIEL,
founder and former Executive Director of Biofortis Mérieux Nutrisciences
Europe to Director of Development and Medical Affairs, effective as of
October 1st 2018.
“Murielle CAZAUBIEL’s introduction to the VALBIOTIS management team
provides an opportunity for the Company, at the time when it accelerates
the international development of VALEDIA®,
prepares the industrial production and a possible reimbursement.
Murielle combines her specialized skills in clinical research with a
leadership profile, working in close connection with our scientific,
economic and regulatory environment. Both an entrepreneur and
experienced manager in the field of clinical nutrition and health
research, she also brings to the table her firsthand experience in the
analysis of the microbiota and a strong focus on bio-informatics,
including the processing of Big-Data. She has all the qualities needed
to help take VALBIOTIS to the next level, to create the necessary
bridges, from preclinical research to industrialization, and to bring
products to market through one or several major players in the health
sector. ”, states Sébastien PELTIER, CEO of VALBIOTIS.
The appointment of Murielle CAZAUBIEL supports VALBIOTIS’s objective to
develop products with a very high level of clinical proof in order to
secure strong health claims in Europe and North America. Her primary
missions will include:
– Clinical development of portfolio products
in conjunction with health authorities, particularly the FDA (Food and
Drug Administration, United States);
– Market access for a
potential reimbursement, particularly VALEDIA®, by supplemental health
insurance and/or public health insurance system
development in collaboration with Pierre Fabre, in order to prepare the
industrial production of VALEDIA® and other products;
Management of regulatory affairs and product quality;
and valorization of research conducted on the intestinal microbiota;
Coordinating relations between VALBIOTIS and clinical opinion leaders,
the medical community, health networks, and the health authorities.
“I am really looking forward to taking on this challenge and to
working with VALBIOTIS in order to start a new chapter in the prevention
of diabetes and metabolic diseases. I believe in the Company’s totally
original and pioneering approach to meeting the rapidly growing,
worldwide health needs of those affected by or at risk for diseases. I
can’t wait to work with the entire team in order to successfully
conclude ongoing and future development programs, bring out value from
the pipeline and explore promising interactions between VALBIOTIS
products and the intestinal microbiota”, declares Murielle CAZAUBIEL.
Scientist, entrepreneur, cluster president: a 360° outlook on life
Murielle CAZAUBIEL has 25 years of experience behind her in nutrition
and health. Before joining VALBIOTIS, she worked, starting in 2015, as
Executive Director of BIOFORTIS EUROPE, one of the leaders in clinical
contract research (CRO – Contract Research Organization). She created
the company herself in 2002, and it would join the MÉRIEUX Group in
2009. BIOFORTIS stands out for its design and completion of experimental
research projects, both preclinical and clinical, with its central
laboratory specializing in metabolic biomarkers, its metagenomics
platform dedicated to analyzing the microbiota and its own clinical
research center. Over the last decade, Murielle CAZAUBIEL has led a team
responsible for the creation and development of clinical trial
management at the Nantes University Hospital (CHU).
From 2012 to 2018, she acted as President of the French cluster
“Atlanpole Biotherapies”, which aims to introduce new therapies and
speed up the development of personalized medicine, by facilitating
research programs between academics and manufacturers.
VALBIOTIS currently employs more than 35 members of staff, of whom
75% work in Research & Development.
VALBIOTIS is a French Research & Development
company committed to scientific innovation for preventing and combating
metabolic diseases. Its products are made for manufacturers in the
agri-food and pharmaceutical industries. VALBIOTIS particularly focuses
on solutions to prevent type 2 diabetes, NASH (nonalcoholic
steatohepatitis), obesity and cardiovascular diseases.
was founded in La Rochelle in early 2014 and has formed numerous
partnerships with top academic centers in France and abroad, including
the La Rochelle University, the CNRS and the Clermont Auvergne
University located in Clermont-Ferrand. These partnerships have enabled
VALBIOTIS to benefit from strong financial leverage, particularly thanks
to experts and technical partners who support its projects. The Company
is now located on 3 sites in France – Périgny, La Rochelle (17) and Riom
(63) – and has an American office in Boston (MA).
VALBIOTIS is a
member of the “BPI Excellence” network and received the “Innovative
Company” status accorded by BPI France. VALBIOTIS has also been awarded
“Young Innovative Company” status and has received major financial
support from the European Union for its research programs by obtaining
support from the European Regional Development Fund (ERDF).
Find out more about VALBIOTIS:
ISIN code: FR0013254851
Mnemonic code: ALVAL
Carole Rocher / Marc
Delaunay, +33 5 46 28 62 58
Stéphane Ruiz, +33 1 56 88 11 14
Guillaume de Chamisso, +33 6 85 91
Rebecca JOHN / Patrick TILL, +1 646 378 2935